Welcome to our dedicated page for Merit Med Sys SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Merit Medical Systems, Inc. (NASDAQ: MMSI) provide detailed information on the company’s financial condition, operations, risk factors, and material events as a Utah‑incorporated medical device and healthcare technology company. Through Forms 10‑K and 10‑Q, investors can review net sales by segment, gross profit, operating expenses, and other key metrics for Merit’s Cardiovascular and Endoscopy businesses, along with discussions of risks related to regulation, reimbursement, supply chain, acquisitions, and market conditions.
Merit also uses Form 8‑K to report significant developments. Recent 8‑K filings have furnished press releases on quarterly and preliminary revenue results, financial guidance, and non‑GAAP measures such as constant currency revenue, non‑GAAP operating margin, non‑GAAP net income, and non‑GAAP earnings per share. Other 8‑Ks disclose leadership and board changes, including the appointment of a new President and Chief Executive Officer and related compensation arrangements, as well as transitions in board roles.
Additional 8‑K filings document acquisition activity and product updates. Merit has reported signing and closing an asset purchase agreement to acquire the C2 CryoBalloon device and related technology, including the proposed purchase consideration and the expected impact on revenue and earnings measures. The company has also furnished press releases on updates to its WRAPSODY Cell‑Impermeable Endoprosthesis product, including commercialization and reimbursement developments.
On this page, Stock Titan presents Merit’s SEC filings with real‑time updates from EDGAR and AI‑powered summaries that explain the context and key points of each document. Investors can quickly scan annual reports (Form 10‑K), quarterly reports (Form 10‑Q), and current reports (Form 8‑K) to understand segment performance, non‑GAAP reconciliations, acquisition terms, leadership changes, and risk disclosures. Filings related to executive appointments and compensation, as well as transaction‑related disclosures, help users analyze governance and incentive structures alongside the company’s operating and financial trends.
MERIT MEDICAL SYSTEMS INC director Fred P. Lampropoulos filed a Form 4 reporting his status as an insider. The summarized data show no reported purchases, sales, exercises, gifts, or other equity transactions in the covered period, and no derivative positions listed.
Merit Medical Systems has acquired View Point Medical in a merger, making View Point a wholly owned subsidiary and adding its OneMark Detection Imaging System and OneMark Tissue Markers to Merit’s therapeutic oncology portfolio. Total consideration, including assumed liabilities, is about $140 million, with $90 million paid in cash at closing and two deferred payments of $25 million each due by the first and second anniversaries of closing.
From April 1 through year-end 2026, the deal is projected to add $2–$4 million of revenue and dilute previously forecast non-GAAP earnings per share by about $0.05, including roughly $2.0 million of lower interest income on cash used. For 2027, revenue contribution is projected at $14–$16 million, with at least 20% annual sales growth, about 70% non-GAAP gross margins and accretion to non-GAAP operating margins, while remaining dilutive to GAAP earnings in 2026–2027 and accretive thereafter.
Merit Medical Systems, Inc. is asking shareholders to vote on director elections, executive compensation and new equity plans at its 2026 virtual annual meeting on May 13, 2026. Items include four director nominees, an advisory Say-on-Pay vote, and approval of 2026 equity incentive and employee stock purchase plans.
Management highlights 2025 performance, including $1.516 billion in revenue, $297 million in operating cash flow and a 59% five-year total shareholder return. The proposed 2026 Equity Incentive Plan would authorize up to 2,700,000 shares, supplementing the existing 2018 long-term incentive plan.
The Vanguard Group filed an amended Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Merit Medical Systems Inc common stock as a result of an internal realignment. The amendment states that certain Vanguard subsidiaries now report disaggregated holdings following an internal reorganization referenced to SEC Release No. 34-39538 (January 12, 1998), and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries. The filing lists the issuer address as 1600 West Merit Parkway, South Jordan, UT, and is signed by Ashley Grim on 03/27/2026.
Merit Medical Systems’ chief legal officer and secretary, Lloyd Brian G., reported multiple equity awards in common stock. On February 26, 2026, he acquired several blocks of shares at $0.00 per share as grants, including restricted stock units that vest in scheduled annual installments, each RSU converting into one common share when vested.
Additional shares were issued after the compensation committee determined performance conditions were met for performance stock units granted on February 28, 2023. He also surrendered 5,778 shares at $78.02 per share to cover payroll and income taxes, with no shares sold in the open market. The filing also notes existing non‑qualified stock options that become exercisable in 25% annual installments beginning on various prior grant dates.
Merit Medical Systems’ chief operating officer Neil W. Peterson reported new equity awards and a related tax share surrender. He acquired 7,690 restricted stock units that vest in three equal annual installments, each RSU converting into one common share when it vests. He also received 17,002 common shares after the company’s Compensation and Talent Development Committee determined performance conditions under earlier performance stock units granted on 02/28/2023 had been met. To cover payroll and income taxes, he surrendered 6,061 common shares to the company at $78.02 per share, with no open-market sale involved.
Aronson Martha Goldberg reported acquisition or exercise transactions in this Form 4 filing.
Merit Medical Systems director and President and CEO Martha Goldberg Aronson reported an equity award of 28,198 shares of common stock in the form of restricted stock units. These RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, contingent on her continued service. After this grant, she directly holds 47,792 common shares, aligning a portion of her compensation with the company’s future performance.
Merit Medical Systems’ chief human resources officer, Michel J. Voigt, reported equity awards and related tax withholding in company stock. On February 26, 2026, he received three stock awards totaling 31,101 shares of common stock at no purchase price, including restricted stock units and performance-based shares.
Footnotes state that two awards are restricted stock units vesting in scheduled installments, and one reflects earned performance stock units granted on February 28, 2023. Voigt then surrendered 6,698 shares back to the issuer at $78.02 per share to cover payroll and income taxes, with no open-market sale. Following these transactions, he directly held 46,127 common shares, plus additional non-qualified stock options and 15 shares held indirectly through a 401(k) plan.
Merit Medical Systems’ Chief Commercial Officer Christian Adam Smith reported multiple equity awards and related tax withholding in company stock. On February 26, 2026, he acquired 8,203, 6,409 and 6,762 shares of common stock at $0 per share through grants and the settlement of performance stock units.
Footnotes state two awards are restricted stock units that vest in scheduled annual installments over two or three years, each RSU converting into one share upon vesting. An additional 2,018 shares were surrendered back to the company at $78.02 per share to cover payroll and income taxes, with no shares sold in the open market.